billHR8792Event Wednesday, May 13, 2026Analyzed

Multigenerational Caregiving Data Act

Neutral

Summary

The Multigenerational Caregiving Data Act (HR 8792) is a procedural, data-collection-only bill that authorizes no funding and creates no procurement mandate. Introduced on May 13, 2026, and referred to committee, it requires one federal population survey to add a voluntary question about unpaid multigenerational caregiving. Market impact is negligible.

See which stocks are affected

Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.

Already have an account? Log in

Key Takeaways

  • 1.HR 8792 authorizes zero spending and creates no procurement mandate — it is a data-collection-only bill with no market impact.
  • 2.The bill is in early legislative stages (referred to committee) with only 3 cosponsors and no Senate companion, making passage unlikely.
  • 3.No publicly traded company faces a material revenue or cost impact from this legislation.

Market Implications

No market implications. The bill authorizes $0 in spending, creates no regulatory burden or benefit for any industry, and has a <10% probability of passage in its current form. Investors should not trade on this legislation.

Full Analysis

1) WHAT HAPPENED: On May 13, 2026, Rep. Houlahan (D-PA) introduced HR 8792, the Multigenerational Caregiving Data Act. The bill was referred to the House Committee on Oversight and Government Reform. It is in very early legislative stages with only three cosponsors and no companion Senate bill. The bill is a simple data-collection mandate. 2) THE MONEY TRAIL: The bill authorizes exactly zero dollars. It directs the HHS Secretary to ensure that at least one major federal population survey includes a question identifying multigenerational caregivers, with cognitive and field testing required. There is no penalty for non-compliance, no new program created, and no procurement mandate. This is a purely informational requirement. 3) STRUCTURAL WINNERS AND LOSERS: There are no material winners or losers. The bill does not change funding, regulation, or competitive dynamics for any industry. Federal IT contractors ($IBM, $LDOS, $CACI, $SAIC) could see trivial task orders to adjust survey instruments, but these are below the threshold of materiality for any publicly traded company. No healthcare company, employer, or insurer is affected because the bill does not mandate employer action, reporting, or benefit changes. 4) COMPETITIVE LANDSCAPE: The federal survey market is already served by incumbents like the Census Bureau, Bureau of Labor Statistics, and HHS agencies. A single question addition does not shift competitive positions. No new markets are created. 5) TIMELINE: The bill requires implementation within 3 years of enactment and a report to Congress 2 years after implementation. However, the bill has not progressed past committee referral. With only 3 cosponsors (all House members) and no Senate companion, passage in the current Congress is unlikely without significant additional support.

Intelligence Surface

Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures

Unconfirmed

No confirming evidence found yet from contracts, insider trades, or congressional activity

$$IBM● Neutral

What the bill does

Data collection mandate with agency flexibility to modify question format, requires cognitive and field testing, voluntary response. No penalties or procurement requirement.

Who must act

Secretary of Health and Human Services, in consultation with Census Bureau and NCHS/CDC

What happens

Agencies must add one voluntary survey question but have broad discretion over wording, placement, and survey instrument. Estimated incremental operational cost is negligible relative to existing survey budgets.

Stock impact

IBM's federal consulting and legacy IT systems integration contracts may see incremental demand for survey instrument design and data management, but the dollar value is trivial (<$5M annually) and not material to IBM's $60B+ revenue base.

$$LDOS● Neutral

What the bill does

Data collection mandate with testing requirement; Leidos provides IT modernization and survey infrastructure services to federal statistical agencies.

Who must act

Secretary of Health and Human Services, in consultation with Census Bureau and NCHS/CDC

What happens

Agencies must add one voluntary survey question with cognitive and field testing. Minor contract task order potential for survey system adjustments.

Stock impact

Leidos holds contracts with Census Bureau and HHS for IT infrastructure. A single survey question modification represents a low-value task order (<$2M) — not material to LDOS's ~$15B revenue.

Related Presidential Actions

Executive orders & memoranda affecting the same sectors or companies

Exec OrderMay 19, 2026

Integrating Financial Technology Innovation into Regulatory Frameworks

This executive order directs federal financial regulators to review and streamline regulations that hinder fintech innovation, particularly for small and emerging firms, and requests the Federal Reserve to evaluate expanding access to its payment accounts and services for non-bank and digital asset firms. It aims to reduce barriers to entry and encourage partnerships between fintech firms and traditional financial institutions, with specific deadlines for reviews and reports.

Exec OrderApr 30, 2026

Promoting Efficiency, Accountability, and Performance in Federal Contracting

This executive order mandates that federal agencies default to using fixed-price contracts for procurement, shifting away from cost-reimbursement models. It requires written justification and senior-level approval for any non-fixed-price contract over certain dollar thresholds (e.g., $10M for most agencies, $100M for the Department of War), and directs agencies to review and renegotiate their 10 largest non-fixed-price contracts within 90 days. The order also tasks OMB with implementation guidance and the Federal Acquisition Regulatory Council with proposing regulatory amendments within 120 days.

Exec OrderApr 18, 2026

Accelerating Medical Treatments for Serious Mental Illness

This executive order directs the FDA to prioritize review and facilitate 'Right to Try' access for psychedelic drugs, including ibogaine compounds, that have received Breakthrough Therapy designation for serious mental illnesses. It also allocates $50 million from HHS to support state programs advancing these treatments and mandates collaboration between HHS, FDA, VA, and the private sector to increase clinical trial participation and data sharing for these drugs. The Attorney General is further directed to expedite rescheduling reviews for approved Schedule I psychedelic substances.